… to execute on our strategy.” Recent Progress Continue to advance AX-0810 for patients suffering from cholestatic … cardiovascular risk. ProQR plans to present and publish additional preclinical data from these two pipeline programs … Chardan Genetic Medicines Conference panel discussion on “ ADAR RNA Editing: Unlocking New Therapeutic Opportunities ”. …
… initial pipeline targets expected in late 2022/early 2023 Additional pivotal trial recommended by EMA for sepofarsen … (MAA). In light of this feedback and in order to continue advancement of the portfolio of ophthalmic product … may selectively enter additional partnerships designed to advance and capture the full potential value of the platform. …
… upfront payment and equity investment ProQR is eligible to additionally receive up to approximately $ 1. 25 billion in … oligonucleotides, or EONs, designed to recruit endogenous ADAR enzymes (Adenosine Deaminases Acting on RNA) to a selected target …
… been enrolled in a Phase 1/2 clinical trial of QR-110 in adults and children with LCA 10. Interim data are expected in … the vision loss associated with Usher syndrome type 2A. ADAR A-to-I RNA editing expert Dr. Peter A. Beal was appointed to ProQR’s scientific advisory board. LEIDEN, the Netherlands, May 09, 2018 (GLOBE …
… molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer EONs are designed to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an Inosine (I) in the RNA …
… ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides … the Company’s runway and deliver on its commitment to advance RNA therapies for diseases with high unmet need. … its RNA editing technology in 2014, it has established a leading IP estate in the ADAR editing space, a first industry …
… effective strategies to increase RNA editing yields of ADARs using chemical modifications and oligonucleotide design. Additionally highlighted was the potential of the Axiomer … molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer ® EONs are …
… platform uses the body’s own editing machinery called ADAR to make single nucleotide edits in RNA,” said Gerard … as targets in our collaboration with Eli Lilly. With broad applicability, and a leading patent portfolio in the ADAR editing space, Axiomer ® …
… as of end of Q2 providing runway into mid-2026, plus additional potential milestones from Lilly partnership … mid-2026, we look forward to continued execution as we advance our science and pipeline programs.” Recent Progress … P-705 ). ProQR scientists showed for the first time in the ADAR RNA editing field in vivo proof of target engagement …